OICR News / Tag

Radiopharmaceuticals and chemical probes

Browse news tagged Radiopharmaceuticals and chemical probes.

Browse all news

Filters

Discover the latest news and insightsDiscover the latest news and insights

All Collaboration Commercialization Talent Technology

All Video Article

Tagged stories

CommercializationTreatment

New CPDC spinout company aims to become global leader in developing and distributing radiopharmaceuticals

AtomVie Global Radiopharma is the latest company launched by the OICR-supported centre The Centre for Probe Development and Commercialization’s (CPDC) newest spinout company has now launched as AtomVie Global Radiopharma Inc. On August 24, the…

ArticleSep 14, 2022

Collaboration

OICR joins European consortium to ‘enable and unlock biology in the open’

OICR's Drug Discovery Program and the Structural Genomics Consortium join Europe’s new large-scale collaboration focused on generating open-access chemical tools for disease research and drug development Developing a new drug is a long, arduous and…

ArticleJun 16, 2020

Commercialization

Ontario centre attracts national attention for probe research, development and commercialization

The Centre for Probe Development and Commercialization (CPDC) awarded $10.5 million to expand molecular imaging probe work in Ontario Translating new scientific discoveries into products and moving those products to the market is a challenging…

ArticleAug 02, 2018

Commercialization

FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A

Addition of new investors builds on Ontario’s next-gen radiotherapies and cancer innovations TORONTO, ON (September 25, 2017) – Ontario oncology innovations investor FACIT congratulates Fusion Pharmaceuticals (“Fusion”), a developer of novel targeted alpha particle radiotherapies,…

ArticleOct 04, 2017

TechnologyTreatment

How chemical probes can boost cancer research

Guest post by David Uehling, PhD, Ontario Institute for Cancer Research, on behalf of the Chemistry In Cancer Research Working Group, part of the American Association for Cancer Research (AACR). The quest for a new cancer drug…

ArticleFeb 10, 2017

Commercialization

FACIT invests in new CPDC spin-out company to aid development of potent radiotherapeutic

In December, the Fight Against Cancer Innovation Trust invested in Fusion Pharmaceuticals to assist in the development of FPX-01, a potent new alpha-emitting radiotherapeutic being developed in Hamilton, Ontario. Early testing has shown a great…

ArticleMar 16, 2016

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Radiopharmaceuticals and chemical probes

Discover the latest news and insightsDiscover the latest news and insights

Tagged stories

New CPDC spinout company aims to become global leader in developing and distributing radiopharmaceuticals

OICR joins European consortium to ‘enable and unlock biology in the open’

Ontario centre attracts national attention for probe research, development and commercialization

Cancer solved together — in your inbox

FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A

How chemical probes can boost cancer research

FACIT invests in new CPDC spin-out company to aid development of potent radiotherapeutic